Standard BioTools
LAB
155 hedge funds and large institutions have $273M invested in Standard BioTools in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 24 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
5% more call options, than puts
Call options by funds: $20K | Put options by funds: $19K
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.51% less ownership
Funds ownership: 78.71% → 76.2% (-2.5%)
3% less funds holding
Funds holding: 159 → 155 (-4)
29% less capital invested
Capital invested by funds: $387M → $273M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$8.33M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$4.04M |
| 3 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$2.46M |
| 4 |
SCM
Sone Capital Management
New York
|
+$2.14M |
| 5 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$765K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.82M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.71M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$4.71M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$3.93M |
| 5 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$2.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KFAS
176
Keating Financial Advisory Services
Manhattan,
Kansas
| – | -$515 | -402 | Closed |
|
|
S
177
SignatureFD
Atlanta,
Georgia
| – | -$406 | -317 | Closed |
|
|
UFPG
178
United Financial Planning Group
Hauppauge,
New York
| – | -$320 | -250 | Closed |
|
179
US Bancorp
Minneapolis,
Minnesota
| – | -$293 | -229 | Closed |
|
LAB Hedge Fund Activity: Q1 2026 in Review
155 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2026, worth a combined $273M — down 29% from $387M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LAB positions and 24 closed out — a net gain of 1 holder — while 50 added to existing stakes and 46 trimmed.
The largest buyer was MAK Capital One, adding an estimated $8.33M. The largest seller was Morgan Stanley, cutting an estimated $5.82M.
- 155 institutional investors held Standard BioTools (LAB) as of Q1 2026, down from 159 in Q4 2025.
- Funds reported $273M of Standard BioTools stock for Q1 2026, down 29% quarter-over-quarter.
- 25 funds opened new Standard BioTools positions in Q1 2026 and 24 closed out, a net change of +1 holder.
- The largest Standard BioTools buyer in Q1 2026 was MAK Capital One, an estimated $8.33M added.
- The largest Standard BioTools seller in Q1 2026 was Morgan Stanley, an estimated $5.82M sold.
Based on aggregated 13F filings for Q1 2026.